Akut Graft Versus Host Hastalığı: Kısa Bir Derleme

Amaç & Hipotez:Akut graft‐versus‐host hastalığı (GvHD), allojeneik hematopoetik kök hücre nakli (alloHKHN) sonrasında görülebilen önemli bir komplikasyondur.

📊

Temel Bulgular & Veri:Akut GvHD (aGvHD) insidansı yaklaşık %30-50 oranında görülmektedir.

💡

Sonuç & Katkı:Bu yazıda aGvHD patobiyolojisi, klinik bulguları, profilaksisi ve tedavisi özetlenecektir.

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Özet

Akut graft‐versus‐host hastalığı (GvHD), allojeneik hematopoetik kök hücre nakli (alloHKHN) sonrasında görülebilen önemli bir komplikasyondur. Akut GvHD (aGvHD) insidansı yaklaşık %30-50 oranında görülmektedir. AlloHKHN yapılan hastalarda GvHD proflaksisi önemlidir. aGvHD gelişen hastalarda başlangıç tedavisi steroiddir. Steroide yanıtsız aGvHD’de prognoz kötüdür. Bu yazıda aGvHD patobiyolojisi, klinik bulguları, profilaksisi ve tedavisi özetlenecektir.

Abstract

Graft‐versus‐host disease (GvHD) is an important complication that can be observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Acute GvHD (aGvHD) is seen after alloHSCT and the incidence of aGvHD is around 30%-50%. aGvHD prophylaxis is essential in patients undergoing allo-HSCT. Initial therapy for aGvHD is steroids. Prognosis is poor in aGvHD patients not responding to steroids. In this article, the pathobiology, clinical findings, prophylaxis, and treatment of aGvHD will be summarized.

🔖

Bu Makaleye Atıf Yap

KELKİTLİ, E., GÖKER, H., ALADAĞ, E. (2022). Akut Graft Versus Host Hastalığı: Kısa Bir Derleme. Turkish Journal of Hematology, Cilt: 37 - Sayı: 1, 1–4. https://ajindex.com/articles/606637

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, UrbanoIspizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307
Lee SE, Cho BS, Kim JH, Yoon JH, Shin SH, Yahng SA, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant 2013;48:587-592
Chao NJ. Graft-versus-host disease: the viewpoint from the donor T cell. Biol Blood Marrow Transplant 1997;3:1-10
Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001;29:259-277
Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966;62:21-78
Toubai T, Mathewson ND, Magenau J, Reddy P. Danger signals and graftversus-host disease: current understanding and future perspectives. Front Immunol 2016;7:539
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956
Ali AM, DiPersio JF, Schroeder MA. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review. Biol Blood Marrow Transplant 2016;22:1552-1564
Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014;49:168-173
Ram R, Storb R. Pharmacologic prophylaxis regimens for acute graft-versushost disease: past, present and future. Leuk Lymphoma 2013;54:1591-1601
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, F